Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019204 (
hepatocellular carcinoma
)
71,386
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Phosphatidylinositol-3-kinase (PI3K) is a well-known regulator of cell division, motility, and survival in most cell types. Recently, we characterized a novel protein that we call PI3K Interacting Protein 1 (
PIK3IP1
), which binds to the p110 catalytic subunit of PI3K and reduces its activity in vitro. Little is known about the role of
PIK3IP1
in normal and neoplastic growth in vivo. Proper liver function and development depend on intact PI3K signal transduction; when dysregulated, the PI3K pathway is linked to the development of liver cancer. To begin to dissect the contribution of
PIK3IP1
to hepatic PI3K signaling in vivo and to liver tumorigenesis in particular, we formulated the following hypothesis: because
PIK3IP1
down-regulates PI3K signaling and uncontrolled PI3K signaling is associated with liver cancer, then
PIK3IP1
-mediated down-regulation of the PI3K pathway should inhibit
hepatocellular carcinoma
(
HCC
) development. To test this idea, we generated transgenic mice overexpressing
PIK3IP1
in hepatocytes in a mouse strain prone to develop
HCC
. Isolated
PIK3IP1
transgenic mouse hepatocytes showed blunted PI3K signaling, DNA synthetic activity, motility, and survival compared with controls. In vivo, spontaneous liver tumorigenesis was significantly dampened in the transgenic animals. This was accompanied by decreased hepatic PI3K activity and reduced hepatocyte proliferation in the transgenics compared with controls. We also observed that human
HCC
expressed less
PIK3IP1 protein
than adjacent matched liver tissue. Our data show that
PIK3IP1
is an important regulator of PI3K in vivo, and its dysregulation can contribute to liver carcinogenesis.
...
PMID:PIK3IP1, a negative regulator of PI3K, suppresses the development of hepatocellular carcinoma. 1863 11
Obese individuals are both insulin resistant and have high levels of circulating free fatty acids (FFAs). In cell culture, saturated but not unsaturated fatty acids induce endoplasmic reticulum (ER) stress. We hypothesized that chronic exposure to low dose fatty acids would significantly attenuate the acute stress response to a saturated fatty acid challenge and that unsaturated fatty acids (oleate) would be more protective than saturated fatty acids (palmitate). The ER stress response to palmitate was reduced after low dose fatty acid exposure in human
hepatoma
cells. Palmitate and oleate gave distinctive transcript responses, both acutely and after chronic low dose exposure. Differentially regulated pathways included lipid, cholesterol, fatty acid, and triglyceride metabolism, and IkappaB kinase and nuclear factor kappaB kinase inflammatory cascades. Oleate reduced palmitate-induced changes significantly more than low dose palmitate and completely blocked palmitate-induced phosphoinositide 3 kinase inhibitor (
PIK3IP1
) as well as induction of GADD45A and B. These changes are predicted to alter the PI3 kinase pathway and the pro-apoptotic p38 MAPK pathway. We recapitulated the oleate response by small interfering RNA-mediated block of
PIK3IP1
stimulation with palmitate and significantly protected cells from palmitate-mediated ER stress. We show that transcriptional responses to oleate and palmitate are distinct, broad, and often discordant. We identified several potential candidates that may direct the transcriptional networks and demonstrate that
PIK3IP1
partially accounts for the protective effects of oleate.
...
PMID:Distinct gene expression profiles characterize cellular responses to palmitate and oleate. 2041 17
There are some controversies about the involvement of microRNA (miR)-19a-3p in
hepatocellular carcinoma
(
HCC
) biology, even though many studies have shown that it plays an important role in cancer. In this study, we found that miR-19a-3p is usually overexpressed in
HCC
tissues compared with corresponding peritumorous tissues, and its expression was associated with tumor size and poor overall survival. MiR-19a-3p promoted cell proliferation significantly, and more cells were found in the S phase. In vivo, miR-19a-3p promoted liver tumor growth, and more
HCC
cells were found in the active cell cycle. Sequencing and bioinformatics analysis predicted that
PIK3IP1
is a likely target gene of miR-19a-3p, and we next confirmed it by luciferase and rescue assays. Altogether, our data showed an important role of
PIK3IP1
downregulation by miR-19a-3p in
HCC
progression, and the miR-19a-3p-
PIK3IP1
-AKT pathway may be a potential therapeutic target.
...
PMID:MicroRNA-19a-3p regulates cell growth through modulation of the PIK3IP1-AKT pathway in hepatocellular carcinoma. 3220 18